The aforementioned means that indistinctly of the molecular classification of breast cancer to which the cell lines belong, they can express leptin, adiponectin, and its receptors, allowing for the possibility of a future treatment for triple-positive breast cancer patients, patients with negative breast cancer, and patients with triple-negative breast cancer with mutations in BRCA1. The gene discussed is BRCA1; the disease is breast carcinoma.